Xenon Pharmaceuticals Inc. (XENE) stock
XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$37.04−0.52 (-1.38%)
Close on Nov 20, 2026Market cap $3.59BP/E –Yield –
Xenon Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Xenon Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$441.59M. For fiscal 2025 it was -$373.07M. The highest annual figure on record is $11.11M in fiscal 2014.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$373.07M | – |
| FY2024 | Dec 31, 2024 | -$279.30M | – |
| FY2023 | Dec 31, 2023 | -$214.05M | – |
| FY2022 | Dec 31, 2022 | -$129.14M | – |
| FY2021 | Dec 31, 2021 | -$78.99M | – |
| FY2020 | Dec 31, 2020 | -$31.30M | – |
| FY2019 | Dec 31, 2019 | -$42.82M | – |
| FY2018 | Dec 31, 2018 | -$38.04M | – |
| FY2017 | Dec 31, 2017 | -$32.58M | – |
| FY2016 | Dec 31, 2016 | -$24.82M | – |
| FY2015 | Dec 31, 2015 | -$9.36M | -184.3% |
| FY2014 | Dec 31, 2014 | $11.11M | +14.4% |
| FY2013 | Dec 31, 2013 | $9.71M | – |
| FY2012 | Dec 31, 2012 | -$3.15M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$123.16M | – |
| Q1 FY2026 | Mar 31, 2026 | -$112.33M | – |
| Q4 FY2025 | Dec 31, 2025 | -$109.77M | – |
| Q3 FY2025 | Sep 30, 2025 | -$96.34M | – |
| Q2 FY2025 | Jun 30, 2025 | -$94.23M | – |
| Q1 FY2025 | Mar 31, 2025 | -$72.74M | – |
| Q4 FY2024 | Dec 31, 2024 | -$77.48M | – |
| Q3 FY2024 | Sep 30, 2024 | -$73.68M | – |
| Q2 FY2024 | Jun 30, 2024 | -$69.10M | – |
| Q1 FY2024 | Mar 31, 2024 | -$59.04M | – |
| Q4 FY2023 | Dec 31, 2023 | -$53.70M | – |
| Q3 FY2023 | Sep 30, 2023 | -$55.68M | – |
| Q2 FY2023 | Jun 30, 2023 | -$55.62M | – |
| Q1 FY2023 | Mar 31, 2023 | -$49.05M | – |
| Q4 FY2022 | Dec 31, 2022 | -$43.33M | – |
| Q3 FY2022 | Sep 30, 2022 | -$38.13M | – |
| Q2 FY2022 | Jun 30, 2022 | -$30.32M | – |
| Q1 FY2022 | Mar 31, 2022 | -$17.37M | – |
| Q4 FY2021 | Dec 31, 2021 | -$24.84M | – |
| Q3 FY2021 | Sep 30, 2021 | -$15.60M | – |
| Q2 FY2021 | Jun 30, 2021 | -$22.50M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.06M | – |
| Q4 FY2020 | Dec 31, 2020 | -$12.92M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.70M | – |
| Q2 FY2020 | Jun 30, 2020 | -$646.00K | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.03M | – |
| Q4 FY2019 | Dec 31, 2019 | -$11.60M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.95M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.51M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.76M | – |
| Q4 FY2018 | Dec 31, 2018 | -$8.45M | – |
| Q3 FY2018 | Sep 30, 2018 | -$14.19M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.59M | – |
| Q1 FY2018 | Mar 31, 2018 | -$7.81M | – |
| Q4 FY2017 | Dec 31, 2017 | -$8.05M | – |
| Q3 FY2017 | Sep 30, 2017 | -$8.64M | – |
| Q2 FY2017 | Jun 30, 2017 | -$7.89M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.99M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.46M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.33M | – |
See a number that looks wrong?